Special Issue

Nanomaterials and Nanotechnology in Biomedical Research

Message from the Guest Editor

This Special Issue aims to highlight these innovations in drug delivery, biosensing, regenerative medicine, and theranostics using nanomaterials such as nanoparticles, quantum dots, and nanocomposites while also discussing novel fabrication techniques, biocompatibility challenges, and the clinical translation of nanomedicine. With the rise of artificial intelligence. nanomedicine has integrated Al-driven algorithms in nanoparticle design, and machine learning aids in drug delivery, just to name a few. This Special Issue examines this role of artificial intelligence and nanotechnology in precision medicine. By showcasing innovative research, this Special Issue aims to foster collaboration and accelerate the integration of nanotechnology into modern biomedical applications with the goal of advancing patient care and personalized medicine.

Guest Editor

Dr. Doğa Kavaz

Department of Bioengineering, Cyprus International University, Mersin 10, 99258 Nicosia, Turkey

Deadline for manuscript submissions

closed (31 October 2025)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/238217

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).